Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)
Urinary System Neoplasm
Astellas Pharma Global Development, Inc.antibody_drug_conjugatePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
25 Active assets in the Urinary System Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Normal Human Serum Albumin Region Skane | Phase 4 | BB |
Docetaxel Sandy Srinivas | Phase 3 | BB |
Prednisolone Eli Lilly and Company | Phase 3 | B |
Volitinib AstraZeneca | Phase 3 | B |
Abemaciclib Eli Lilly and Company | Phase 3 | B |
View all 42 →
Same molecule, other indications
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →